Merit Financial Group’s MaxCyte MXCT Stock Holding History

Merit Financial Group’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-14,654	Closed	-$18K	–	2513
2026 Q2	$18K	Buy	+14,654	New	+$14.6K	﹤0.01%	2334

Other funds holding MXCT

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Brooklands Fund Management London, United Kingdom $782M AUM 0.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Willis Investment Counsel Gainesville, Georgia $1.97B AUM 25.29% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Merit Financial Group's MXCT Position: Q3 2026 in Review

Merit Financial Group sold out of MaxCyte (MXCT) in Q3 2026, closing a stake of 14,654 shares — an estimated $18K sold.

Merit Financial Group first reported a position in MXCT in Q2 2026 and held it in 1 quarter. The position peaked at $18K in Q2 2026. 60 funds tracked by Wall St. Rank hold MXCT as of Q3 2026.

Merit Financial Group reported no remaining MaxCyte position as of Q3 2026 after selling out during the quarter.
Merit Financial Group sold 14,654 MaxCyte shares in Q3 2026, an estimated $18K.
Merit Financial Group first reported a position in MaxCyte in Q2 2026 and held it in 1 quarter.
Merit Financial Group's MaxCyte position peaked at $18K in Q2 2026.
60 funds tracked by Wall St. Rank held MaxCyte as of Q3 2026.

Based on Merit Financial Group's 13F filing for Q3 2026, filed 6 Nov 2026.